title: Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain.
abstract: The number and localization of effector cells to the tumor site are crucial elements for immune rejection of solid tumors. However, for cerebral malignancies, antitumor responses need to be finely tuned to avoid neuropathologic consequences. In this study, we determine factors that regulate CTL localization and tumoricidal function after intracerebral implantation of tumors expressing model Ag. H-2(bxd) mice implanted with a CW3(+) murine glioma lacking H-2K(d) molecules necessary to present the CW3(170-179) epitope demonstrate cross-priming of H-2K(d)-restricted CTL, and moreover, Ag-dependent accumulation of functional H-2K(d)/CW3(170-179)-specific CTL within the tumor bed. This implicates a role for cross-presentation not only in priming, but also in retention of fully differentiated CTL in the tumor stroma at the effector stage of the response. Modulating cross-presentation of Ag may be the key in regulating specific immune responses in the brain: either by augmenting protective responses or by down-modulating destructive autoimmune reactions.
authors.affiliation: Laboratory of Tumour Immunology, Division of Oncology, Department of Neurosurgery, University Hospital Geneva, Rue Micheli-du-Crest 24, 1211 Geneva 14, Switzerland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Calzascia
authors.forename: Wilma
authors.initials: W
authors.lastname: Di Berardino-Besson
authors.forename: Rick
authors.initials: R
authors.lastname: Wilmotte
authors.forename: Frédérick
authors.initials: F
authors.lastname: Masson
authors.forename: Nicolas
authors.initials: N
authors.lastname: de Tribolet
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Dietrich
authors.forename: Paul R
authors.initials: PR
authors.lastname: Walker
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D000938:Antigen-Presenting Cells / Q000276:immunology / Q000378:metabolism; D000956:Antigens, Viral / Q000276:immunology / Q000378:metabolism; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000502:physiology; D005260:Female; D005910:Glioma / Q000276:immunology* / Q000473:pathology; D007117:Immunization, Secondary; D008213:Lymphocyte Activation / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000473:pathology; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000473:pathology
chemical_list: D000956:Antigens, Viral; D018984:Epitopes, T-Lymphocyte